🇺🇸 FDA

Company profile · Sponsor

Wyeth

Wyeth is now a wholly owned subsidiary of Pfizer

E649F09 · NMPA pharma CN
Pipeline
9
Drugs
0
Patents
0

Quick answer

Wyeth (E649F09) is a pharma company. headquartered in CN. listed on NMPA. NovaPharmaNews links 9 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E649F09
Exchange NMPA
Company type pharma
Headquarters CN

Pipeline (9)

Search pipeline →

  1. DVS SR

    Wyeth

    Depressive Disorder, Major

    phase 3 small molecule completed

    1 trial

  2. tigecycline

    Wyeth

    Community-Acquired Infections

    phase 3 small molecule completed

    1 trial

  3. Double-blind investigational anti-arrhythmic

    Wyeth

    Arrhythmias

    phase 2 small molecule terminated

    1 trial

  4. SAM-315

    Wyeth

    Alzheimer Disease

    phase 1 small molecule completed

    1 trial

  5. Etanercept , Methotrexate

    Wyeth

    Rheumatoid Arthritis

    approved small molecule completed

    1 trial

  6. ReFacto

    Wyeth

    Hemophilia A

    approved small molecule terminated

    1 trial

  7. Tigecycline

    Wyeth

    Skin Diseases, Bacterial

    approved small molecule completed

    1 trial

  8. cyclosporine or tacrolimus

    Wyeth

    Graft Rejection

    approved small molecule completed

    1 trial

  9. tigecycline

    Wyeth

    Appendicitis

    approved small molecule completed

    1 trial

Frequently asked questions

What is Wyeth?

Wyeth (E649F09) is a pharma company. headquartered in CN. listed on NMPA. NovaPharmaNews links 9 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Wyeth sponsor?

We track 9 ClinicalTrials.gov-linked programs for Wyeth, including DVS SR and 8 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Wyeth company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.